Opendata, web and dolomites

IRIS-1 SIGNED

IRIS Feasibility Study – Phase 1

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "IRIS-1" data sheet

The following table provides information about the project.

Coordinator
RINICARE LIMITED 

Organization address
address: RIVERWAY HOUSE MORECAMBE ROAD
city: LANCASTER
postcode: LA1 2RX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme /SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RINICARE LIMITED UK (LANCASTER) coordinator 50˙000.00

Mappa

 Project objective

The IRIS Feasibility Study – Phase 1 (IRIS-1) Project aims to assess the overall feasibility of the introduction of the Intensive-care Risk prediction and Identification System (IRIS), an innovative real-time patient monitoring and personalised risk prediction and identification system, into the healthcare sector. Thousands of surgery patients in Europe and worldwide die each year due to complications during the post- operative period and thousands more survive with disabilities, making the economic burden of post-operative complications in surgery patients amount to hundreds of millions of euros annually. It is widely accepted that early recognition of complications can reduce their severity and consequences: continuous patient monitoring systems and risk scoring systems are available but they lack suitability for patients in intensive care, trust calculations at time intervals, analyse solely a fraction of available patient data, cannot detect multi-dimensional trends, rely on arbitrary thresholds to generate alarms and cannot be customised for each patient. Thus, there are increased mortality rates and re-admission rates to hospital, contributing to the overwhelming financial and economic burden of public healthcare. Addressing serious morbidities, such as heart, renal and respiratory failures, and capable of surpassing human limitations in processing large volumes of patient data, IRIS is a real-time adaptive and dynamic patient monitoring and risk prediction and identification system, sensitive to variable interactions and capable of incorporating patient data to identify trends in individual patients’ physiological parameters that predict post- operative complications. Developed by RINICARE, IRIS will assist clinical staff to identify at an early stage serious complications in surgery patients, allowing a prompt medical intervention, thus improving the chance of a successful health outcome and contributing to the sustainability of the healthcare system.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRIS-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRIS-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

BADGER (2017)

CalScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

Read More  

ABC-S (2018)

Acoustic Blood Cells Sorter

Read More  

SDS-OmiProbe (2017)

Revolutionary opto-biological methodology for aggressive HER2 cancer

Read More